Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer have?
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer has 753 citations in the OpenAlex counts ScholarIQ stores.
When was Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer published?
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer has 2015 year in the ScholarIQ index.
What is the open-access status of Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer?
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer?
The DOI for Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer is on the source record.
What is the PMID of Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer?
The PMID for Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer is on the source record.
What is the OpenAlex record for Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer?
The OpenAlex for Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer is on the source record.